 In July 2007, "Wired Magazine" reported that Raydiance had signed a deal with the U.S. Federal Drug Administration (FDA) to explore laser therapies, ranging from common laser eye treatments to the cell-by-cell tumor ablation.In addition to serving as CEO of Raydiance, Schuler is managing director of the Draper Fisher Jurvetson Growth Fund and serves on the boards of UBMatrix, Hands On Mobile, UU See, Synthetic Genomics, and Visto.Schuler is an investor in Adirondack Pictures.